CGEN צמיחת רווח נקי למניה השנה Compugen Ltd.

Compugen Ltd. relies on strategic alliances and licensing agreements with pharmaceutical leaders, confirming its partnership-based development model. Growth is driven by successes in creating PVRIG/TIGIT antibodies and payments from partners. The absence of proprietary manufacturing plants, achieved through outsourcing, ensures flexibility. Relative EPS YoY dynamics visualize fundamental shifts, while -174.10 represents the current metric value.

This indicator measures the year-over-year dynamics of net income per share, allowing investors to assess the actual efficiency of business capitalization and detect income stagnation in a timely manner. The current YoY net income per share growth rate of -174.10 reflects the ability of Compugen Ltd. (CGEN) to convert AI developments and payments from Gilead into real financial growth, confirming the fundamental stability of the biotechnological model.